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MicroRNAs (miRNAs) are a recently discovered family of short non-coding RNA molecules of about 19–24 nucleotides in length 
that are involved in regulation of gene expression. These small molecules have been found to regulate genes involved in diverse bio-
logical processes such as cell proliferation, development, differentiation, apoptosis and others. MiRNAs regulate gene expression 
at the post-transcriptional level either by inhibition of the target (mRNA) or by its destruction. Recent studies have shown that 
mRNA deregulation is a basic problem in studying pathogenesis of many malignant tumors. It has been recently shown that miRNAs 
are able to regulate thousands of target genes simultaneously. Thus, the key role of miRNA in carcinogenesis reveals a new layer 
in the molecular architecture of cancer. Patterns of altered miRNA expression in cancer may serve as molecular biomarkers for 
tumor diagnosis, prognosis of disease-specific outcomes, and prediction of therapeutic responses. Furthermore, miRNAs may 
serve as specific targets of new gene therapies.
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INTRODUCTION
Currently, there is reliable evidence that DNA-
sequences in the so-called “junk” genomic regions 
may play an important role in regulation of gene ex-
pression. These regions encode sequences known 
as microRNAs [1, 2], which belong to the class of small 
RNA molecules with a length of 19–24 nucleotides. 
Nearly all eukaryotic organisms have a large number 
of RNAs, which do not encode proteins, and are neither 
ribosomal nor transport RNAs.
Currently, hundreds of human miRNAs have been 
identified. It is estimated that there may be approxi-
mately 1000 miRNAs in the human genome. It is also 
known that a single miRNA can influence on the expres-
sion of several thousands of genes, thus controlling one 
third of the human genome [3]. MicroRNAs are able 
to regulate various biological processes such as cell 
growth (including stem cells), their differentiation and 
death [4], neuroprocesses and immune response [5, 
6]. It becomes evident that these small molecules play 
a key role in biological processes of all systems and de-
regulation of their expression may have negative effect 
on the normal cell growth and differentiation.
More than 50% of genes of miRNA-encoding ge-
nomic loci reside in chromosomal regions unbalanced 
during tumorogenesis. Such miRNAs are called on-
comirs (oncogenic microRNA) [7]. It is well established 
that deregulation of miRNA genes occurs in tumors 
of different localizations, and that miRNAs themselves 
can act as oncogenes (if their genes are amplified 
or hyperexpressed) or tumor suppressor genes 
(in case of deletions or repressions of miRNAs) [8].
There is increasing evidence that the altered miRNA 
expression plays an important role in carcinogenesis 
beginning from genomic localization, regulation at the 
level of transcription and processing and completing 
by post-transcriptional modification of molecules. This 
review presents the main historical events of discov-
ery, biogenesis and disorders in miRNA genes related 
to malignization of human cells.
HISTORY OF microRNA DISCOVERY
The first miRNA, lin-4, was discovered in 1993 by Vic-
tor Ambros and his colleagues while studying hete-
rochronic gene lin-14 in worms. Lin-4 RNA controls 
the timing of Caenorhabditis elegans larval develop-
ment [9]. It encodes a small RNA that is complemen-
tary to sequences in the 3’untranslated region (UTR) 
of lin-14 mRNA and acts as developmental repressor 
of the accumulation of lin-14 protein. This repression 
is essential for synchronization of numerous events 
of C.elegans larval development [10].
However, the most important functions of miRNA 
remained unknown until discovery of another C. 
elegans small RNA molecule, let-7. The lin-4 and 
let-7 genes are nonhomologous and act in a similar 
manner to trigger the transition to late-larval and adult 
stages [11]. Ruvkun et al. (2000) obtained the first 
evidences concerning ability of small RNAs to con-
trol gene expression. These investigators found that 
let-7 RNA expression can be detected in a wide range 
of animal species including vertebrates, ascidian, 
mollusc, annelid and arthropods, further implying 
that small RNA-mediated translational regulation 
may be a widespread gene regulatory model present 
in many animal spices [12].
From the list of discovered and predicted miRNAs, 
several hundreds have been already cloned for human, 
mice, C. elegans, Drosophila and Arabidopsis (see 
http://microrna.sanger.ac.uk) [13]. The large num-
ber of miRNAs and homologous sequences of many 
miRNAs among organisms suggests that these RNAs 
might constitute an abundant component of the gene 
regulatory machinery with an ancient origin [14].
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BIOGENESIS AND MECHANISMS 
OF ACTION OF MicroRNAs
Analysis of 186 miRNA genes provides information 
about the nonrandom distribution of miRNAs genes 
in the human genome. Ninety miRNA genes are lo-
cated in 36 clusters, usually with 2 or 3 genes per 
cluster (median 2.5), and the part of them is located 
within introns of pre-mRNA genes [15].
Despite some differences in miRNA biogenesis be-
tween animals and plants, the most important events 
of this process remain similar. They can be represented 
as follows (by example of the miRNA biogenesis in ani-
mals):
•	gene transcription by RNA-polymerase II and 
formation of primary miRNA gene transcript with 
stem- loop structure (pre-miRNA);
•	formation of miRNA precursor molecules of about 
70 nucleotides in length (pri-miRNA);
•	final stage of maturation of effector 22-nucleotide 
double-stranded miRNA [16].
This space-division and coordinated process re-
quires involvement of several cell complexes. The first 
two phases take place in the nucleus, and molecule 
maturation and gene regulation occur in the cytoplasm.
The primary miRNA molecule, pri-miRNA, have 
a length of about 1000 nucleotides with 7-methyl-
guanosine at the 5’ end and polyA at the 3’ end. The 
pri-miRNAs are initially recognized by Drosha and 
its binding partner DGCR8, which is responsible for 
high-specific binding to immature miRNA molecule. 
The complex comprising these proteins was named 
the microprocessor complex [17, 18] which very con-
servative among all animals. Drosha as a component 
of microprocessor complex asymmetrically cleaves 
both strands of the hairpin stem at sites near the base 
of the primary stem loop, thus releasing a 60-to 70-nu-
cleotide molecule known as pre-miRNA, that has 
a 5’ phosphate and a 2-nucleotide 3’overhang [19].
The pre-miRNAs are transported to the cytoplasm 
by Exportin-5, in a Ran-GTP-dependent manner 
[20, 21]. The further cytoplasmic processing is that 
Dicer, a second RNase-III endonuclease, together with 
transactivation-responsive RNA-binding protein (TRBP) 
cleaves pre-miRNA molecule and forms two double-
stranded nucleotides [22, 23, 24]. One strand of the 
miRNa duplex (plus-strand) binds to a large protein 
complex in an ATP-independent manner and forms 
RNA-induced silencing complex (RISC) [16]. The strand 
incorporated into RISC becomes the mature miRNA 
and guides the RISC complex to the target miRNA [25]. 
Binding to single-stranded RNA molecule is realized via 
PAZ-domain of Argonaute protein, and PIWI-domain 
is likely provides effector-nuclease function [26]. Ago 
protein is a compulsory component of RISC and it plays 
a key role in posttranscriptional gene silencing (PTGS). 
Four proteins of this family bound to miRNA through 
complementarity were found in humans [27].
More recently, it has become apparent that some 
miRNA can not use major biogenesis pathways. Mature 
of such molecules as miR-320 and miR-484 does not 
depend on Drosha and DGCR proteins [28], and miR-
451 matures by a Dicer-independent mechanism [29, 
30]. Drosha-and DGCR-8-independent miRNAs repre-
sent a group of the so-called mirtrons and tailed mirtrons. 
Pre-miRNAs of these molecules mature by means 
of splicing and exonuclease cutting of strands [31, 32].
Interaction of miRNA with a target RNA in most 
cases results in gene repression. As opposed to other 
classes of small molecules of RNA microRNAs silence 
genes different from which their primary transcripts 
originate (hetero-silencing) [33].
Near perfect matching of the 5’end of miRNA (the 
seed region) to the target site within the 3’UTR leads 
to translational inhibition. The features within the 3’UTR 
of a particular mRNA that would accurately predict 
miRNA targeting have been expanded to include prox-
imity of miRNA-binding sites, AU (adenosine, uracil) rich 
environments flanking the seed region, and preferential 
sites within the UTR at both ends [34]. Such regulation 
leads to decrease in protein level of the target gene with 
no decreasing in the number of mRNA molecules per cell.
An alternate pathway of miRNA is thought to lead not 
to translational inhibition but rather to mRNA destabi-
lization through adenosine/uridine rich elements [35]. 
Ago2 protein bound to miRNA within the RISC complex 
is responsible for the target mRNA destruction [36]. 
These noncanonical types miRNA:mRNA interaction 
have not been extensively studied and thus cannot 
be bioinformatically predicted; however, they could 
be equally consequential to the better studied seed-
matching mechanism leading to translational inhibition.
Recently obtained data have shown the new level 
of gene expression regulation. As shown in Fig. 1, 
the potential mechanisms of miRNA-mediated gene 
regulation are multifactorial and encompass interac-
tions among different mechanisms. 
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Fig. 1. Potential microRNA regulation mechanisms. Cis-
regulation: microRNA direct targeting the mRNA and regulating 
the expression of the target gene at post-transcriptional levels 
(e.g., enhance mRNA degradation and inhibit translation). 
Trans-regulation: Following the expression changes of microRNA 
targeted specific genes (e.g., genes coded for transcription 
factors, genes coded for RNA regulating proteins, and genes 
coded for proteins that will interact with the target protein), 
subsequent effects may alter the transcription of other gene, 
levels of other mRNAs, or interactions among proteins, and thus 
microRNA may exert its functional effects through transregula-
tory mechanism(s) [37]
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Cis-regulation including mRNA repression or mRNA 
decay is realized through the miRNA seed binding 
to the 3’UTR of a particular mRNA. However, it has 
been shown that after expression changes in miRNA-
targeted specific genes (e.g., genes coded for tran-
scription factors, genes coded for RNA regulating 
proteins, and genes coded for proteins that will interact 
with the target protein), subsequent effects may alter 
the transcription of other gene, levels of other mRNAs, 
or interactions among proteins, and thus miRNA may 
exert its functional effects through transregulatory 
mechanism [37].
MicroRNA AND CANCER
Relationship between cancer and miRNA was first 
revealed by Professor G. Calin and co-workers in 2002. 
They suggested that miR-15a and mir16–1 could 
be the tumor suppressors involved in the pathogenesis 
of chronic lymphocytic leukemia because the expres-
sion of these genes is downregulated or suppressed 
in most cases with cell lymphocytic leukemia. Many 
different projects were done in this area since then. 
Many investigators have shown aberrant expression 
profile of some oncomirs between tumor and normal 
tissues [8, 38, 39].
Large-scale investigations on the role of some mi-
croRNA in carcinogenesis were done. Many projects 
are devoted to claster mir-17–92 [15, 40–43], oncosu-
pressor let-7g [11, 44, 45], oncogene mir-21 [46–48] 
and some others.
The link between miRNAs and metastasis has been 
reported but these studies have been conducted 
using cell-lines and xenographic models [49]. On-
comirs (miR-10b, miR-9, miR-31 and miR-335), for 
which aberrant expression in breast cancer has been 
detected, can be taken as an example. The cell-line 
or model-based research cannot be extrapolated 
to humans because it is impossible to determine the 
role of microenvironment, link with disease prognosis 
and many other clinical parameters. However, there 
are literature data on the relationship between the 
level of miRNA expression and clinical-biological pa-
rameters such as survival, recurrence, predisposition 
to tumor progression and metastasis.
MiRNA GENETIC ALTERATIONS IN HUMAN 
CANCERS
Recent studies have shown that alterations in miR-
NA synthesis in human cancers are often related to tu-
mor development, progression and metastasis. There 
is a hypothesis that deregulated synthesis of microR-
NAs, which in turn regulate protein synthesis, is one 
of the most important factors contributing to cancer 
development [50–52].
The finding that miR-15a and miR-16–1 are lo-
cated in a region that is frequently deleted in leukemia 
gave a hint that a connection might exist between 
the genomic position of microRNA and the location 
of cancer-associated genomic regions. Later on, 
deletions of miR-15а and miR-16–1 were also de-
tected in solid tumors, such as pituitary adenomas 
[53], ovarian and breast cancers [54]. Translocation 
of miR-17–92 in acute T-cell leukemia was also shown 
[55]. The mir-142 gene, a marker of haematopoietic 
cells, was found at the breakpoint junction of a t(8;17) 
translocation, which causes an aggressive B cell leu-
kemia due to strong up-regulation of a translocated 
MYC gene [56].
By using bioinformatics and public databases 
of genomic regions that are prone to alteration in can-
cer, such as minimal regions of LOH, minimal regions 
of amplification, common breakpoint regions and 
fragile sites, Calin et al. (2004) analyzed the location 
of, known that time, microRNAs in the human genome 
and found they frequently reside (> 50%) in such ge-
nomic regions. Later on, these results were confirmed 
by different methods and at different cancers [39, 54, 
57]. Hua Dong et al. (2011) [58] indentified 409 trans-
expression quantitative trait locus and 27 trans- miRNA 
eQTL for loss of heterozygosity (LOH) mutation in glio-
blastoma.
Amplification of certain genes also plays a role 
in carcinogenesis, for example amplification of the 
mir-17–92 cluster in lymphoma [59]. By analizing 
miR-17–19 cluster at the 13q31 locus, He et al. (2005) 
found that expression of 5 microRNAs is significantly 
correlated with the gene dosage of С13orf25 across 
the all analyzing cell lines. Zhang et al. (2006), using 
an array-based comparative genomic hybridization 
(aCGH), showed correlation between gene copy 
number of microRNA and cancer. Starczynowski 
et al. (2010) [60] showed that seventy-seven percent 
(542 of 706) of miRNAs mapped to leukemia-asso-
ciated copy-number alterations in the cell lines, but 
only 18% (99 of 542) of these miRNAs are expressed 
above background levels. Differential PCR revealed 
deletions in miR-186 (15%), miR-135a-1 (33%), 
miR-548d-1 (42%), miR-548d-2 (21%) and miR-
512–2 (33%) genes, whereas deletion or amplification 
was detected in miR-135b and miR-135a-2 in 23% and 
in 15% of medulloblastomas, respectively [61].
MicroRNA biogenesis malfunctions can result 
in serious consequences for a cell and ultimately 
for the whole organism. Deletions, disorders in the 
processing pathway or abuse of regulation of micro-
environment play a certain role in cell transformations 
[62]. Deletions or malfunction of microRNA biogen-
esis (Dicer or DGCR8 proteins) can lead to changes 
in proliferation and differentiation of stem cells [63, 
64]. Malfunction of Dicer due to deletion of its locus 
most frequently leads to malignization. It is notably that 
Dicer is haploinsufficient oncosupressor that is even 
deletion of a part of this gene could lead to malig-
nization [65]. Kumar et al. (2009) [66] showed that 
27% of various tumors have a hemizygous deletion 
of the gene that encodes DICER1. TARBP2 is mutated 
in some colon and gastric cancers with microsatellite 
instability, and TARBP2 frameshift mutations correlate 
with DICER1 destabilization [67].
Of particular interest is the fact that DGCR8 was 
originally identified as a gene that maps to the chro-
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mosomal region 22q11.2, a region whose monoallelic 
deletion accounts for >90% of patients with DiGeorge 
syndrome, the most common human genetic deletion 
syndrome [68].
Genetic changes in the 3´ UTR of target genes 
can both create or destroy a miRNA binding site. For 
example, Jiang et al. (2010) [69] identified a muta-
tion in the miR-155 binding site of the SOCS1 3´ UTR 
in a breast tumor that reduced miR-155 repression. 
Chromosomal translocations can remove miRNA 
binding sites from their regulated oncogenes [70]. 
Alternative polyadenylation can relax miRNA-mediated 
regulation of known oncogenes [71]. Cooperativity 
or competition of miRNAs for mRNA target site binding 
with other RBPs, such as ELAVL1 (HuR), DND1 and 
PUM1, can also de-repress target expression [72–75].
EPHIGENETIC ALTERATIONS OF miRNA 
IN HUMAN CANCERS
Recently, accumulating studies have shown that 
a subgroup of miRNAs is regulated epigenetically. 
The finding that CpG islands within introns can act 
as promoters suggests that perhaps intronic miRNAs 
that have CpG islands upstream within the same intron 
could be transcribed from their own promoters that are 
regulated by DNA methylation [76, 77].
Scott et al. (2006) [78] showed that in breast can-
cer cells, inhibition of the histone deacetylase (HDAC) 
rapidly altered the expression levels of nearly 30 mi-
croRNAs, indluding let-7a. Moreover, Saito et al. (2006)
[79] found that the combined treatment of human blad-
der cancer cells with a DNA-demethylating agent and 
an inhibitor of HDAC caused the significant upregulation 
(>3-fold) of 17 out of 313 microRNAs. Another example 
of important role of epigenetic alterations is role of miR-
9–1 in breast cancer [80]. MicroRNA regulate proteins 
that play role in epigenetic repression of genes DNMT, 
HDAC, HMGA2 and PcG [81–83]. Thereby, there is over-
lapping of functions and crossregulation of regulatory 
epigenetic agents and microRNAs.
Hypermethylation of miR-9 loci is observed 
in various malignant tissues, including breast, lung, 
colon, head and neck cancers, melanoma and 
acute lymphoblastic leukemia [80, 84–86]. Wong 
et al. (2011) [87] showed that in primary lymphoma 
samples, miR-124–1 preferentially hypermethylated 
in B- or NK/T-cell lymphomas and associated with 
reduced miR-124 expression. Also the methylation 
levels of the CpG islands of miR-34b ⁄ c [85, 88], miR-
137 [89] are correlated with mature expression levels 
in various cancers.
miR-203 is located in fragile genomic region, and 
it targets ABL1 and BCRABL1, an oncogenic fusion 
gene generated by the Philadelphia translocation [90]. 
Epigenetic silencing of miR-203 enhances activation 
of the BCR-ABL1 fusion gene, resulting in an elevation 
of tumor cell growth rate. Also it is frequently observed 
in other types of malignancies, including oral cancer, 
hepatocellular carcinoma, etc. [89, 91].
Many transcriptional factors regulate microRNA ex-
pression through type-specific manner and many mi-
croRNAs are under regulation of oncosupressors such 
as TP53, MYC and RAS [92], for example miR-21 which 
are regulated by RAS gene [93]. MicroRNA molecules 
correlate with their transcriptional regulators through 
the feedback, so it is clear that disorder at one stage 
can lead to malfunction of the whole system.
From these observations it may be concluded that 
miRNA genes undergo different genetic alterations 
during tumorigenesis. Biogenesis disorders, deletions, 
translocations, increase in gene copy number and epi-
genetic alterations have been found to lead to changes 
in microRNA expression and tissue-/site-specific pat-
tern of microRNA, thus influencing on pathogenesis 
and molecular-genetic characteristics of cancer.
CONCLUSION
Recent researches concerning the role of miRNA 
in human cancer pathogenesis have provoked a great 
interest of both the research scientists and clinical on-
cologists. The high specificity of miRNAs compared with 
mRNAs indicates that these small molecules can serve 
as highly informative cancer biomarkers [94, 95]. Fur-
thermore, miRNA can be extracted from a wide range 
of tissue and body fluid samples, that also make them 
useful potential markers for the molecular analysis [96].
The perspective of using miRNA in clinical practice 
is not restricted by only early detection of the disease. 
It is also possible to use them in cancer therapy. In this 
case it is necessary to rely on dualistic functions 
of miRNA. If miRNA acts as tumor suppressor, it is nec-
essary to increase the level of its expression by either 
increasing copying or deleting repression of the 
encoded gene or guiding the mature miRNA into the 
tumor cell. If miRNA acts as oncogene, it is necessary 
to inhibit its expression. One of the approaches to in-
hibit miRNA expression is the use of “sponges” which 
represent mRNA and have multiple complementary 
sites for particular miRNAs. High expression of these 
mRNA-sponges leads to specific inhibition of the whole 
family of miRNA with similar binding sites [97].
It is also necessary to take into consideration side 
effects of miRNA -based therapy. miRNAs and inter-
fering RNAs (siRNAs) share many common features. 
However, interfering RNA is able to repress the target 
mRNA both in perfect matching of seed region within 
the 3’UTR of a particular mRNA and in nearly perfect 
complementarity. Although siRNAs can be easily de-
signed to target one specific target with perfect comple-
mentarity, it can be difficult to computationally predict 
repression of other target genes through imperfect 
sequence marching, via a miRNA-like mechanism [98]. 
These unpredictable interactions can lead to negative 
side effects of miRNA therapy [99, 100]. In this respect, 
miRNAs are preferential because they are able to rec-
ognize and repress a large number of target mRNAs. 
However, this is suggested not to result in side effects 
because miRNA therapy will be directed to the recov-
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ery of physiological level of miRNA expression, which 
is detected in the normal tissue.
Before clinical use of miRNAs, some problems 
should be solved. They include both the role of miRNA 
in cellular pathways and mechanisms of regulation 
and expression and the search for the critical miRNAs 
involved in cancer development. The influence of anti-
tumor therapy on the levels of miRNA expression has 
not been extensively studied. Few data are reported 
in the literature about the effect of chemotherapeutical 
agents on the miRNA expression levels in tumor cells 
that in turn can result in drug resistance [101, 102].
Both the basic and clinical researches in the miRNA 
field are currently very important. The results of these 
studies will allow the researches to determine the 
miRNA status in normal and transformed cells as well 
as to assess the possibility of application of miRNA 
molecules for modulation of cell growth, proliferation 
and metabolism. Understanding of the role of miR-
NAs is allowing new insights on the molecular basis 
of cancers, and new biomarkers for cancer diagnosis, 
prognosis and therapy.
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